KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Supernus Pharmaceuticals (SUPN) EBIAT (2016 - 2026)

Supernus Pharmaceuticals has reported EBIAT over the past 15 years, most recently at -$4.1 million for Q4 2025.

  • Quarterly EBIAT fell 126.78% to -$4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$38.6 million through Dec 2025, down 152.19% year-over-year, with the annual reading at -$38.6 million for FY2025, 152.19% down from the prior year.
  • EBIAT was -$4.1 million for Q4 2025 at Supernus Pharmaceuticals, up from -$45.1 million in the prior quarter.
  • Over five years, EBIAT peaked at $38.5 million in Q3 2024 and troughed at -$45.1 million in Q3 2025.
  • The 5-year median for EBIAT is $6.8 million (2021), against an average of $7.5 million.
  • Year-over-year, EBIAT surged 2496.63% in 2024 and then tumbled 9637.9% in 2025.
  • A 5-year view of EBIAT shows it stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then tumbled by 95.39% to $1.2 million in 2023, then soared by 1204.51% to $15.3 million in 2024, then tumbled by 126.78% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBIAT are -$4.1 million (Q4 2025), -$45.1 million (Q3 2025), and $22.5 million (Q2 2025).